Pluri Inc. (PLUR), the Israeli cell-therapy and regenerative-medicine company formerly known as Pluristem Therapeutics, has endured a punishing multi-year decline that has left its shares trading near $0.90. Against that backdrop, the most widely discussed near-term price objective for the stock is not a Wall Street consensus but a single, symbolic number: $1.00, the Nasdaq minimum bid price threshold that determines whether the company can retain its exchange listing.
Because Pluri lacks a credible multi-analyst consensus, the $1.00 figure here is not an analyst price target. Data aggregators still display a lone $12.00 target from Alliance Global Partners (analyst Matthew Venezia), which initiated coverage in June 2025 — more than a year ago and before the stock's most recent leg lower. Weiss Ratings, which issues letter-grade ratings rather than price targets, has maintained "Sell"-oriented grades on Pluri through 2026. With only one outdated target and no current sell-side coverage of note, the standard analyst-average method does not apply.
The $1.00 objective instead reflects an identifiable, publicly discussed milestone: Nasdaq requires listed companies to maintain a minimum bid price of $1.00 per share, and market commentary around Pluri has centered on whether the stock can climb back above that level to ease delisting and compliance concerns. It is a realistic, near-term price objective grounded in the listing rules rather than a valuation-based forecast.
Pluri shares have traded in a wide 52-week range spanning roughly $0.91 to $5.68, and the stock has recently been quoted near $0.90 after breaking below prior lows. From that level, reaching $1.00 implies upside of about 10% — a modest move in percentage terms, though one that would carry outsized weight given its regulatory significance.
The path toward $1.00 is more likely to be driven by sentiment, liquidity, and corporate actions than by fundamental earnings, because Pluri currently generates only about $1 million in trailing revenue against a net loss measured in the tens of millions of dollars. Absent a shift in fundamentals, any move back above $1.00 would need to be sustained to satisfy listing requirements.
Several factors could help the shares reclaim $1.00. Pluri's proprietary 3D cell-expansion technology underpins a diversified platform spanning regenerative medicine, foodtech, agtech, and CDMO services, which provides multiple potential revenue avenues beyond a single drug. Non-dilutive funding — such as the roughly €7.5 million European Union Horizon Europe grant announced in September 2026 for the PROTO osteoarthritis program using its PLX-PAD cells — supports development without immediate shareholder dilution. Insider and strategic ownership, including a large disclosed holder, can also provide some stability. In the very short term, positive sentiment, a favorable clinical or partnership announcement, or a reduction in the pace of equity issuance could be enough to lift the stock back above the $1.00 level.
The obstacles are substantial. Pluri is a micro-cap with a market capitalization in the low tens of millions of dollars, negative stockholders' equity, and persistent operating losses. The company has a long history of reverse stock splits — including a 1-for-8 split in April 2024 — which is a signal of chronic share-price erosion and dilution. Clinical risk is real: the company's Phase 3 trial of PLX-PAD for muscle injury following hip-fracture surgery failed its primary endpoint in 2022. Continued cash burn, further dilution, or another clinical disappointment could push the shares lower and keep them below the $1.00 compliance threshold. The wider downtrend itself is also a headwind, as investors may remain reluctant to bid up a stock with no clear path to profitability.
The $1.00 level now functions as both a psychological round number and a hard regulatory threshold, making it the most important resistance level for Pluri in the near term. Below it, the recent low near $0.91 marks immediate support. The stock's sustained decline from a 52-week high near $5.68 has left a deeply entrenched downtrend, with prior support zones having repeatedly given way. A decisive, sustained move above $1.00 — rather than a brief intraday touch — is what would matter for compliance purposes, and that would require both buying interest and a stabilization in the rate of dilution.
Because the $1.00 objective is tied to exchange listing rules rather than a formal research horizon, there is no single agreed-upon timeframe; the lone $12 analyst target, by contrast, was set as a longer-horizon research view that has not been updated. Investors should monitor quarterly filings for cash position, operating-cash burn, and any new equity raises, since those determine how much dilution pressure the stock faces. Other items to watch include progress and data from the PLX-PAD osteoarthritis program, updates on foodtech and CDMO partnerships, any Nasdaq deficiency or compliance notices, and broader risk appetite for speculative micro-cap biotechnology, which can swing sentiment sharply regardless of fundamentals.
For investors tracking fast-moving, low-priced names like Pluri, the AI Daily Buy/Sell Signals from Tickeron offer a systematic way to stay oriented. The tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. Rather than relying on emotion or scattered headlines, traders can use these signals to discover opportunities, monitor existing positions, and spot shifting trends more efficiently. Exploring the AI Daily Buy/Sell Signals can help bring structure to a market that often moves on sentiment alone.
The question of whether Pluri can reach $1.00 is less a valuation debate than a test of near-term stability. The $1.00 level is a publicly discussed, listing-driven objective rather than an analyst consensus, and the move required from roughly $0.90 is modest at about 10%. The strongest supports are the company's diversified platform, non-dilutive grant funding, and the symbolic importance of reclaiming compliance. The principal obstacles are unrelenting cash burn, negative equity, repeated dilution and reverse splits, and a clinical record that includes a failed Phase 3 study. The lone $12 analyst target is too stale to treat as a meaningful signal. Investors should watch the cash runway, dilution pace, and any Nasdaq compliance actions above all else, and should not treat $1.00 — or any higher figure — as a guaranteed outcome.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that PLUR and KOD have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PLUR and KOD's prices will move in lockstep.
| Ticker / NAME | Correlation To PLUR | 1D Price Change % | ||
|---|---|---|---|---|
| PLUR | 100% | +1.79% | ||
| KOD - PLUR | 29% Poorly correlated | +1.18% | ||
| ENSC - PLUR | 29% Poorly correlated | +0.03% | ||
| LENZ - PLUR | 28% Poorly correlated | +0.24% | ||
| MGNX - PLUR | 26% Poorly correlated | -4.13% | ||
| STRO - PLUR | 26% Poorly correlated | +0.88% | ||
More | ||||